Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by N-methyl-D-aspartate receptor antagonist, memantine

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 2, 1997, Pages 854-865

  Popik, Piotr ^a   Danysz, Wojciech ^b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

KAPPA OPIATE RECEPTOR; MEMANTINE; METHADONE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALOXONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVERSION; DOSE RESPONSE; DRUG ABUSE; DRUG WITHDRAWAL; MALE; MAZE TEST; MOTIVATION; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTITUTION THERAPY; TASK PERFORMANCE;

ANIMALS; FEEDING BEHAVIOR; MALE; MAZE LEARNING; MEMANTINE; MEMORY; MORPHINE; NALOXONE; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; REINFORCEMENT (PSYCHOLOGY); SPACE PERCEPTION; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 0030942167     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (102)

1. ADAMS, M. L., MORRIS, D. L., BRASE, D. A. AND DEWEY, W. L.: Stereoselective effect of morphine on antinociception and endogenous opioid peptide levels in plasma but not cerebrospinal fluid of dogs. Life Sci. 48: 917-924, 1991.
2. BALL, J. C. AND Ross, A.: Follow-up study of 105 patients who left treatment. In The Effectiveness of Methadone Maintenance Treatment. Patients, Programs, Services, and Outcome, ed. by J. C. Ball and A. Ross, pp. 176-187, Springer-Verlag, New York, 1991.
3. BARNES, C. A., DANYSZ, W. AND PARSONS, C. G.: Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur. J. Neurosci. 8: 565-571, 1996.
4. BEN-ELIYAHU, S., MAREK, P., VACCARINO, A. L., MOGIL, J. S., STERNBERG, W. F. AND LIEBESKIND, J. C.: The NMDA receptor antagonist MK-801 prevents long-lasting non-associative morphine tolerance in the rat. Brain Res. 575: 304-308, 1992.
5. BESPALOV, A., DUMPIS, M., PIOTROVSKY, L. AND ZVARTAU, E.: Excitatory amino acid receptor antagonist kynurenic acid attenuates rewarding potential of morphine. Eur. J. Pharmacol. 264: 233-239, 1994.
6. BESPALOV, A., ZVARTAU, E. E. AND BEARDSLEY, P. M.: Kynurenic acid attenuates rewarding potential but fails to alter discriminative stimulus properties of opiates in rodents. Fed. Eur. Pharmacol. Soc. (Milan) 31: 113, 1995.
7. BHARGAVA, H. N. AND MATWYSHYN, G. A.: Dizocilpine (MK-801) blocks tolerance to the analgesic but not to the hyperthermic effect of morphine in the rat. Pharmacology 47: 344-350, 1993.
8. BINDRA, D.: How adaptive behavior is produced: A perceptual-motivation alternative to response reinforcement. Behav. Brain Sci. 1: 41-91, 1978.
9. BORMANN, J.: Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur. J. Pharmacol. 166: 591-592, 1989.
10. BRENT, P. J. AND CHAHL, L. A.: Enhancement of the opiate withdrawal response by antipsychotic drugs in guinea-pigs is not mediated by sigma binding sites. Eur. Neuropsychopharmacol. 3: 23-32, 1993.
11. BUBSER, M., KESEBERG, U., NOTZ, P. K. AND SCHMIDT, W. J.: Differential behavioural and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats. Eur. J. Pharmacol. 229: 75-82, 1992.
12. CAPPENDIJK, S. L., DE VRIES, R. AND DZOLJIC, M. R.: Excitatory amino acid receptor antagonists and naloxone-precipitated withdrawal syndrome in morphine-dependent mice. Eur. Neuropsychopharmacol. 3: 111-116, 1993.
13. CARAMANOS, Z. AND SHAPIRO, M. L.: Spatial memory and N-methyl-D-aspartate receptor antagonists APV and MK-801-memory impairments depend on familiarity with the environment, drug dose, and training duration. Behav. Neurosci. 108: 30-43, 1994.
14. CARR, G. F., FIBIGER, H. C. AND PHILLIPS, A. G.: Conditioned place preference as a measure of drug reward. In The Neuropharmacological Basis of Reward, ed. by J. Liebman and S. J. Cooper, pp. 264-319, Clarendon Press, Oxford, 1989.
15. CHARNEY, D. S., STERNBERG, D. E., KLEBER, H. D., HENINGER, G. R. AND REDMOND, D. E. JR.: The clinical use of clonidine in abrupt withdrawal from methadone. Effects on blood pressure and specific signs and symptoms. Arch. Gen. Psychiatry 38: 1273-1277, 1981.
16. CHEN, H. S. V., PELLEGRINI, J. W., AGGARWAL, S. K., LEI, S. Z., WARACH, S., JENSEN, F. E. AND LIPTON, S. A.: Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: Therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 12: 4427-1436, 1992.
17. COLPAERT, F. C.: Narcotic cue and narcotic state. Life Sci. 20: 1097-1108, 1977.
18. COLPAERT, F. C., LAL, H., NIEMEGEERS, C. J. AND JANSSEN, P. A.: Investigations on drug produced and subjectively experienced discriminative stimuli. I. The fentanyl cue, a tool to investigate subjectively. Life Sci. 16: 705-715, 1975.
19. COLPAERT, F. C., NIEMEGEERS, C. J. E. AND JANSSEN, P. A. J.: Fentanyl and apomorphine: Assymetrical generalisation of discriminative stimulus properties. Neuropharmacology 15: 541-545, 1976.
20. DANYSZ, W., GOSSEL, M., ZAJACZKOWSKI, W., DILL, D. AND QUACK, G.: Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? Case of amantadine and memantine. J. Neural Transm. Park. Dis. Dement. Sect. 7: 155-166, 1994.
21. DANYSZ, W., PARSONS, C. G., BRESINK, I. AND QUACK, G.: Glutamate in CNS disorders: A revived target for drug development. Drug News Perspect. 8: 261-277, 1995a.
22. DANYSZ, W., ZAJACZKOWSKI, W. AND PARSONS, C. G.: Modulation of learning processes by ionotropic glutamate receptor ligands. Behav. Pharmacol. 6: 455-174, 1995b.
23. DI CHIARA, G. AND IMPERATO, A.: Drugs abused by humans preferentially increase synaptic dopamine concentratin in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U.S.A. 85: 5274-5278, 1988.
24. DITZLER, K.: Efficacy and tolerability of memantine in patients with dementia syndrome. A double blind, placebo controlled trial. Arzneimittelforschung 41: 773-780, 1991.
25. DONZANTI, B. A. AND URETSKY, N. J.: Effects of excitatory amino acids on locomotor activity after bilateral microinjection into the rat nucleus accumbens: Possible dependence on. Neuropharmacology 22: 971-981, 1983.
26. EDDY, N. B., HALBACH, H., ISBELL, H. AND SEEVERS, M. H.: Drug dependence: Its significance and characteristics. Bull. W.H.O. 32: 721-733, 1965.
27. ELLIOTT, K., MINAMI, N., KOLESNIKOV, Y. A., PASTERNAK, G. W. AND INTURRISI, C. E.: The NMDA receptor antagonists, LY74614 and MK801, and the nitric oxide synthase inhibitor, ng-nitro-l-arginine, attenuate analgesic tolerance to the μ-opioid morphine but not to κ-opioids. Pain 56: 69-75, 1994.
28. FILE, S. E. AND FERNANDES, C.: Dizocilpine prevents the development of tolerance to the sedative effects of diazepam in rats. Pharmacol. Biochem. Behav. 47: 823-826, 1994.
29. FRENCH, E. D.: Phencyclidine and the midbrain dopamine system:- Electrophysiology and behavior. Neurotoxicol. Teratol. 16: 355-362, 1994.
30. GIANUTSOS, G. AND LAS., H.: Effect of loperamide, haloperidol and methadone in rats trained to discriminate morphine from saline. Psychopharmacologia 41: 267-270, 1975.
31. GIANUTSOS, G. AND LAL, H.: Selective interaction of drugs with a discriminable stimulus associated with narcotic action. Life Sci. 19: 91-98, 1976.
32. GOLD, M. S., REDMOND, E. D. AND KLEBER, H. D.: Clonidine blocks acute opiate withdrawal symptoms. Lancet 2: 599-601, 1978.
33. GOUDIE, A. J.: Animal models of drug abuse and dependence. In Behavioural Models in Psychopharmacology: Theoretical, Industrial and Clinical Perspectives, ed. by P. Willner, pp. 453-484, Cambridge University Press, Cambridge, 1991.
34. GÖRTELMEYER, R. AND ERBLER, H.: Memantine in the treatment of mild to moderate dementia syndrome: A double-blind placebo-controlled study. Arzneimittelforschung 42: 904-913, 1992.
35. HENRIKSSON, B. G. AND JARBE, T. U. C. Delta 9-Tetracannabinol used as discriminative stimulus for rats in position learning in a T-shaped water maze. Psychonom. Sci. 27: 25-26, 1972.
36. 3 receptor antagonists on behavioural measures of naloxone-precipitated opioid withdrawal. Psychopharmacology 105: 322-328, 1991.
37. HIGGINS, G. A., NGUYEN, P. AND SELLERS, E. M.: The NMDA antagonist dizocilpine (MK801) attenuates motivational as well as somatic aspects of naloxone precipitated opioid withdrawal. Life Sci. 50: PL167-PL172, 1992.
38. JAFFE, J. H.: Pharmacological agents in treatment of drug dependence. In Psychopharmacology. The Third Generation of Progress, ed. by H. Y. Meltzer, pp. 1605-1616, Raven Press, New York, 1987.
39. JARBE, T. U. C.: Drug discrimination learning. Cue properties of drugs. In Experimental Psychopharmacology, pp. 433-479, The Humana Press, Clifton, NJ, 1987.
40. JASINSKI, D. R., JOHNSON, R. E. AND KOCHER, T. R.: Clonidine in morphine withdrawal. Differential effects on signs and symptoms. Arch. Gen. Psychiatry 42: 1063-1066, 1985.
41. JEDEMA, H. P. AND MOGHADDAM, B.: Glutamatergic control of dopamine release during stress in the rat prefrontal cortex. J. Neurochem. 63: 785-788, 1994.
42. 3 receptor antagonists on the discriminative stimulus properties of morphine in rats. Psychopharmacology 112: 111-115, 1993.
43. KALIVAS, P. W., DUFFY, P. AND BARROW, J.: Regulation of the mesocorticolimbic dopamine system by glutamic acid receptor subtypes. J. Pharmacol. Exp. Ther. 251: 378-387, 1989.
44. KHANNA, J. M., KALANT, H., SHAH, G. AND CHAU, A.: Effect of D-cycloserine on rapid tolerance to ethanol. Pharmacol. Biochem. Behav. 45: 983-986, 1993.
45. 1, opioid analgesic tolerance by NCP17742, a novel NMDA antagonist. Life Sci. 53: 1489-1494, 1993.
46. KOLESNIKOV, Y. A., MACCECCHINI, M. L. AND PASTERNAK, G. W.: 1-aminocyclopro-panecarboxylic acid (ACPC) prevents μ and δ opioid tolerance. Life Sci. 55: 1393-1398, 1994.
47. KOOB, G. F.: Neurobiological mechanisms in cocaine and opiate dependence. In Addictive States, ed. by C. P. O'Brien and J. H. Jaffe, pp. 79-92, Raven Press Ltd, New York, 1992.
48. 3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur. J. Pharmacol. 166: 589-590, 1989.
49. KORNHUBER, J. AND QUACK, G.: Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci. Lett. 195: 137-139, 1995.
50. KOYUNCUOGLU, H.: The combination of tizanidine markedly improves the treatment with dextromethorphan of heroin addicted outpatients. Int. J. Clin. Pharmacol. Ther. Toxicol. 33: 13-19, 1995.
51. KOYUNCUOGLU, H. AND SAYDAM, B.: The treatment of heroin addicts with dextromethorphan. A double-blind comparison of dextromethorphan with chloropromazine. Int. J. Clin. Pharmacol. Ther. Toxicol. 28: 147-152, 1990.
52. KREBS, M. O., DESCE, J. M., KEMEL, M. L., GAUCHY, C., GODEHEU, G., CHERAMY, A. AND GLOWINSKI, J.: Glutamatergic control of dopamine release in the rat stroatum: Evidence for presynaptic N-methyl-D-aspartate receptors on dopaminergic nerve terminals. J. Neurochem. 56: 81-85, 1991.
53. KUTSUWADA, T., KASHIWABUCHI, N., MORI, H., SAKIMURA, K., KUSHIYA, E., ARAKI, K., MEGURO, H., MASAKI, H., KUMANISHI, T., ARAKAWA, M. AND MISHINA, M.: Molecular diversity of the NMDA receptor channel. Nature 358: 36-41, 1992.
54. LAYER, R. T., KADDIS, F. G. AND WALLACE, L. J.: The NMDA receptor antagonist MK-801 elicits conditioned place preference in rats. Pharmacol. Biochem. Behav. 44: 245-247, 1993.
55. LITCHFIELD, J. T. AND WILCOXON, F.: A simplified method of a evaluating dose-effects experiments. J. Pharmacol. Exp. Ther. 96: 99-133, 1949.
56. LOTSOF, H. S.: Ibogaine in the treatment of chemical depencency disorders: Clinical perspectives. Bull. Multidisciplinary Association for Psychedelic Studies 5: 16-27, 1995.
57. LUBY, E. D., COHEN, R. C., ROSENBAUM, B., GOTTLIEB, J. S. AND KELLY, R.: Study of a new schizophrenomimetic drug: Sernyl. Arch. Neurol. Psychiatry 81: 363-369, 1959.
58. MARTIN, W. R. AND JASINSKI, D. R.: Physiological parameters of morphine dependence in man-tolerance, early abstinence, protracted abstinence. J. Psychiatr. Res. 7: 9-17, 1969.
59. MISZTAL, M. AND DANYSZ, W.: Comparison of glutamate antagonists in continuous multiple-trial and single-trial dark avoidance. Behav. Pharmacol 6: 550-561, 1995.
60. MISZTAL, M., FRANKIEWICZ, T., PARSONS, C. G. AND DANYSZ, W.: Learning deficits induced by chronic intraventricular infusion of quinolinic acid: Protection by MK-801 and memantine. Eur. J. Pharmacol. 296: 1-8, 1996.
61. MOGHADDAM, B. AND BOLINAO, M. L.: Glutamatergic antagonists attenuate ability of dopamine uptake blockers to increase extracellular levels of dopamine: Implications for tonic. Synapse 18: 337-342, 1994.
62. MUCHA, R. F. AND HERZ, A.: Motivational properties of kappa and μ opioid receptor agonists studied with place and taste preference conditioning. pSychopharmacology 86: 274-280, 1985.
63. MUCHA. R. F., VAN DER KOOY, D., O'SHAUGHNESSY, M. AND BUCENIEKS, P.: Drug reinforcement studied by the use of place conditioning in the rat. Brain Res 243: 91-105, 1982.
64. PANI, L., KUZMIN, A., MARTELLOTTA, M. C., GESSA, G. L. AND FRATTA, W.: The calcium antagonist PN 200-110 inhibits the reinforcing properties of cocaine. Brain Res. Bull. 26: 445-447, 1991.
65. PAPP, M. AND MORYL, E.: Rewarding properties of non competitive and competitive NMDA antagonists as measured by place preference conditioning in rats. Pol. J. Pharmacol. Pharm. 46: 79-81, 1994.
66. PARSONS, C. G., GRUNER, R., ROZENTAL, J., MILLAR, J. AND LODGE, D.: Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 32: 1337-1350, 1993.
67. PARSONS, C. G., QUACK, G., BRESINK, I., BARAN, L., PRZEGALINSKI, E., KOSTOWSKI, W., KRZASCIK, P., HARTMANN, S. AND DANYSZ, W.: Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34: 1239-1258, 1995.
68. PHILLIPS, A. G. AND LE PAINE, F. G.: Reinforcing effects of morphine microinjection into the ventral tegmental area. Pharmacol. Biochem. Behav. 12: 965-968, 1980.
69. PIZZI, W. J. AND COOK, D. F.: Conditioned taste aversion is a confound in behavioral studies that report a reduction in the reinforcing effects of drugs. Pharmacol. Biochem. Behav. 53: 243-247, 1996.
70. POPIK, P., LAYER, R. T., FOSSOM, L., BENVENISTE, M., GETTER-DOUGLAS, B., WITKIN, J. M. AND SKOLNICK, P.: NMDA antagonist properties of the putative antiaddicitive drug, ibogaine. J. Pharmacol. Exp. Ther. 275: 753-760, 1995.
71. POPIK, P., MAMCZARZ, J. AND VETULANI, J.: The effect of electroconvulsive shock and nifedipine on spatial learning and memory in rats. Biol. Psychiatry 35: 864-869, 1994a.
72. POPIK, P., NALEPA, I., MAMCZARZ, J. AND VETULANI, J.: Retrieval associated cholinergic activity and its inhibition by memory updating. Life Sci. 54: 1251-1257, 1994b.
73. POPIK, P. AND SKOLNICK, P.: The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol. Biochem. Behav. 53: 791-798, 1996.
74. PUDIAK, C. M. AND BOZARTH, M. A.: L-NAME and MK-801 attenuate sensitization to the locomotor-stimulating effect of cocaine. Life Sci. 53: 1517-1524, 1993.
75. PULVIRENTI, L. AND KOOB, G. F.: Dopamine receptor agonists, partial agonists and psychostimulant addiction. Trends Pharmacol. Sci. 15: 374-379, 1994.
76. RASMUSSEN, K., FULLER, R. W., STOCKTON, M. E., PERRY, K. W., SWINFORD, R. M. AND ORNSTEIN, P. L.: NMDA receptor antagonists supress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal. Eur. J. Pharmacol. 197: 9-16, 1991.
77. RICE, K. C., JACOBSON, A. E., BURKE, T. R. JR., BAJWA, B. S., STREATY, R. A. AND KLEE, W. A.: Irreversible ligands with high selectivity toward delta and μ opiate receptors. Science 220: 314-316, 1983.
78. ROBINSON, T. E. AND BERRIDGE, K. C.: The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Rev. 18: 247-291, 1993.
79. ROGAWSKI, M. A.: Therapeutic potential of excitatory amino acid antagonists: Channel blockers and 2,3-benzodiazepines. Trends Pharmacol. Sci. 14: 325-331, 1993.
80. ROUNSAVILLE, B. J., KOSTEN, T. R. AND KLEBER, H. D.: Success and failure at outpatient opioid detoxification: evaluating the process of clonidine- and methadone-assisted withdrawal. J. Nerv. Ment. Dis. 173: 103-110, 1985.
81. SHANNON, H. E. AND HOLTZMAN, S. G.: Morphine training dose: a determinant of stimulus generalization to narcotic antagonists in the rat. Psychopharmacology 61: 239-244, 1979.
82. SHAPIRO, M. L. AND CARAMANOS, Z.: NMDA antagonist MK-801 impairs acquisition but not performance of spatial working and reference memory. Psychobiology 18: 231-243, 1990.
83. SHEPPARD, S. G.: A preliminary investigation of ibogaine: Case reports and recommendations for further study. J. Subst. Abuse Treat. 11: 379, 1994.
84. SHOAIB, M. AND STOLERMAN, I. P.: MK-801 attenuates behavioural adaptation to chronic nicotine administration in rats. Br. J. Pharmacol. 105: 514-515, 1992.
85. SPYRAKI, C., FIBIGER, H. C. AND PHILLIPS, A. G.: Attenuation of heroin reward in rats by disruption of the mesolimbic dopamine system. Psychopharmacology 79: 278-283, 1983.
86. TANGANELLI, S., ANTONELLI, T., MORARI, M., BIANCHI, C. AND BEANI, L.: Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs. Neurosci. Lett. 122: 270-272, 1991.
87. TISEO, P. J., CHENG, J., PASTERNAK, G. W. AND INTURRISI, C. E.: Modulation of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY274614: assessment of opioid receptor. J. Pharmacol. Exp. Ther. 268: 195-201, 1994.
88. TISEO, P. J. AND INTURRISI, C. E.: Attenuation and reversal of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist, LY274614. J. Pharmacol. Exp. Ther. 264: 1090-1096, 1993.
89. TROUPIN, A. S., NENDIUS, J. R., CHENG, F. AND RISINGER, M. W.: MK-801. In New Anticonvulsant Drugs, ed. by B. S. Meldrum and R. J. Porter, pp. 191-201, John Libbey, London, 1986.
90. TRUJILLO, K. A. AND AKIL, H.: Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251: 85-87, 1991.
91. TZSCHENTKE, T. M. AND SCHMIDT, W. J.: N-methyl-D-aspartic acid-receptor antagonists block morphine-induced conditioned place preference in rats. Neurosci. Lett. 193: 37-40, 1995.
92. VAN DER KOOY, D., MUCHA, R. F., O'SHAUGHNESSY, M. AND BUCENIEKS, P.: Reinforcing effects of brain microinjections of morphine revealed by conditioned place preference. Brain Res. 243: 107-117, 1982.
93. WENK, G. L., DANYSZ, W. AND MOBLEY, S. L.: MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur. J. Pharmacol. Environ. Toxicol. Pharmacol. 293: 267-270, 1995.
94. WESSINGER, W. D.: Tolerance to and dependence on MK-801 (dizocilpine) in rats. Pharmacol. Biochem. Behav. 49: 1049-1056, 1994.
95. WHITE, N. M. AND CARR, G. D.: The conditioned place preference is affected by two independent reinforcement processes. Pharmacol. Biochem. Behav. 23: 37-42, 1985.
96. WIKLER, A., MARTIN, W. R., PESCOR, F. T. AND EADES, C. G.: Factors regulating oral consumption of an opioid (Etonitazene) by morphine-addicted rats. Psychopharmacologia 5: 55-76, 1963.
97. WISE, R. A. AND BOZARTH, M. A.: A psychomotor stimulant theory of addiction. Psychol. Rev. 94: 469-192, 1987.
98. WOLF, M. E. AND KHANSA, M. R.: Repeated administration of MK-801 produces sensitization to its own locomotor stimulant effects but blocks sensitization to amphetamine. Brain Res. 562: 164-168, 1991.
99. WOLF, M. E., WHITE, F. J. AND HU, X. T.: MK-801 prevents alterations in the mesoaccumbens dopamine system associated with behavioral sensitization to amphetamine. J. Neurosci. 14: 1735-1745, 1994.
100. WOLFER, D. P. AND LIPP, H. P.: A new computer program for detailed off-line analysis of swimming navigation in the Morris water maze. J. Neurosci. Methods 41: 65-74, 1992.
101. YOUNG, A. M., MASAKI, M. A. AND GEULA, C.: Discriminative stimulus effects of morphine: effects of training dose on agonist and antagonist effects of μ opioids. J. Pharmacol. Exp. Ther. 261: 246-257, 1992.
102. ZAJACZKOWSKI, W., QUACK, G. AND DANYSZ, W.: Infusion of (+)-MK-801 and memantine: Contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur. J. Pharmacol. 296: 239-246, 1996.